Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Probiodrug    PBD   DE0007921835

PROBIODRUG (PBD)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
09/17/2018 09/18/2018 09/19/2018 09/20/2018 09/21/2018 Date
3.26(c) 3.3(c) 3.3(c) 3.31(c) 3.3(c) Last
58 438 65 858 73 219 26 835 18 322 Volume
-0.61% +1.23% 0.00% +0.30% -0.30% Change
More quotes
Financials (EUR)
Sales 2018 -
EBIT 2018 -8,72 M
Net income 2018 -9,15 M
Finance 2018 2,80 M
Yield 2018 -
Sales 2019 -
EBIT 2019 -12,8 M
Net income 2019 -15,2 M
Debt 2019 4,83 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 0
Capitalization 27,1 M
More Financials
Company
Probiodrug AG is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease.Its product pipeline includes PQ912, PBD-C06, and PQ1565.The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and... 
More about the company
Latest news on PROBIODRUG
09/05PROBIODRUG : Appoints Dr. Michael Schaeffer as Executive Vice President of Busin..
AQ
09/04PROBIODRUG : Appoints Dr. Michael Schaeffer as Executive Vice President of Busin..
AQ
08/30PROBIODRUG : Reports Financial Results for H1 2018 and Corporate Update
AQ
08/30PROBIODRUG : Slide show half-year results
CO
08/27PROBIODRUG AG : half-yearly earnings release
08/23PROBIODRUG AG : Preliminary announcement of the publication of financial reports..
EQ
08/23PROBIODRUG AG : to Publish First Half 2018 Results on August 30, 2018
AQ
08/21PROBIODRUG : Crossing thresholds
CO
07/13PROBIODRUG AG : Notification and public disclosure of transactions by persons
EQ
07/12PROBIODRUG AG : Notification and public disclosure of transactions by persons
EQ
More news
Sector news : Biotechnology & Medical Research - NEC
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
08/30It seems that the last Probiodrug $PBD hopes rely on the coming subgroup data..
1
08/23Probiodrug AG: Preliminary announcement of the publication of financial repor.. 
08/20update: Probiodrug $PBD +45% in large volumes, someone anticipating good news..
1
08/06Probiodrug $PBD pipeline & newsflow 2018/2019* (June) (* if enough $) 
07/13$792183 AG 1 director bought: A director at Probiodrug Ag bought 4,900 share.. 
More tweets
Qtime:5
News from SeekingAlpha
08/30Probiodrug AG 2018 Q2 - Results - Earnings Call Slides 
2017Probiodrug AG 2017 Q2 - Results - Earnings Call Slides 
2017SNIPPET ROUNDUP : Novartis Enters Advair Generic Race, Biogen Dealt CFO Blow 
2017Biomarin's Rare Disease Approval And Probiodrug's Alzheimer's Play 
2015BP Energy Outlook 2035 Shows More Work Needs To Be Done On Carbon Reduction 
Chart PROBIODRUG
Duration : Period :
Probiodrug Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBIODRUG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 31,5 €
Spread / Average Target 855%
EPS Revisions
Managers
NameTitle
Ulrich Dauer Chief Executive Officer
Erich Maximilian Platzer Chairman-Supervisory Board
Inge Lues Chief Development Officer
Jörg Neermann Member-Supervisory Board
Dinnies Johannes von der Osten Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
PROBIODRUG-68.87%32
CELLTRION, INC.--.--%33 388
IQVIA HOLDINGS INC30.32%25 763
LONZA GROUP18.80%24 291
INCYTE CORPORATION-29.69%14 156
SEATTLE GENETICS, INC.45.35%12 348